FLUDARABINE AND CYCLOPHOSPHAMIDE (FC) VERSUS CYCLOPHOSPHAMIDE, VINCRISTINE AND PREDNISONE (CVP) AS FIRST LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). SINGLE CENTER EXPERIENCE

被引：0
|
作者：
Ionita, H. [1 ]
Chreveresan, L. [1 ]
Mihaescu, R. [1 ]
Ionita, I. [1 ]
Isac, A. [1 ]
Cheveresan, M. [2 ]
Oros, D. [1 ]
Iordache, M. [1 ]
Musta, I. [1 ]
Basa, N. [1 ]
Delamarian, M. [2 ]
机构：
[1] Univ Med & Farm Timisoara, Timisoara, Romania
[2] Cty Hosp, Dept Hematol, Timisoara, Romania
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1203
引用
收藏
页码：468 / 468
页数：1
相关论文
共 50 条
  • [41] Paraneoplastic pemphigus despite treatment with rituximab, fludarabine and cyclophosphamide in chronic lymphocytic leukemia
    Schierl, Michael
    Foedinger, Dagmar
    Geissler, Klaus
    Rappersberger, Klemens
    Feldmann, Robert
    EUROPEAN JOURNAL OF DERMATOLOGY, 2008, 18 (06) : 717 - 718
  • [42] Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As Inital Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia
    Zhu, Huayuan
    Sha, Yeqin
    Miao, Yi
    Qin, Shuchao
    Shen, Hui
    Qiu, Jingyan
    Wu, Wei
    Xia, Yi
    Qiu, Tonglu
    Wang, Li
    Fan, Lei
    Xu, Wei
    Li, Jianyong
    BLOOD, 2022, 140 : 4164 - 4165
  • [43] THE COST-EFFECTIVENESS OF BENDAMUSTINE VERSUS FLUDARABINE FOR THE FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN MEXICO
    Bertwistle, D.
    Munakata, J.
    Wehler, E.
    Leyva, V
    Valencia, A.
    Hernandez, A.
    de la Torre, L.
    Gonzalez, L.
    VALUE IN HEALTH, 2013, 16 (07) : A409 - A409
  • [44] A Molecular Model to Predict Durable Remission after First Line Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia
    Rossi, Davide
    di Bergamo, Lodovico Terzi
    Chiarenza, Annalisa
    Bulian, Pietro
    Visco, Carlo
    Mauro, Francesca Romana
    Morabito, Fortunato
    Cortelezzi, Agostino
    Zaja, Francesco
    Forconi, Francesco
    Laurenti, Luca
    Del Giudice, Ilaria
    De Paoli, Lorenzo
    Vincelli, Iolanda
    Rigolin, Gian Matteo
    Marasca, Roberto
    Perbellini, Omar
    Moreno, Carol
    Del Poeta, Giovanni
    Massaia, Massimo
    Zinzani, Pier Luigi
    Montillo, Marco
    Cuneo, Antonio
    Foa, Robin
    Gattei, Valter
    Gaidano, Gianluca
    BLOOD, 2014, 124 (21)
  • [45] Combined therapy of rituximab, fludarabine and cyclophosphamide (R-FC) as a first-line treatment is safe and efficacious for younger patients with B-cell chronic lymphocytic leukemia (B-CLL).
    Ranze, OP
    Arland, M
    Hoffkes, HG
    BLOOD, 2003, 102 (11) : 355B - 356B
  • [46] Impact and predictors of reducing prescribed doses of fludarabine, cyclophosphamide and rituximab (FCR) in frontline treatment of chronic lymphocytic leukemia (CLL)
    Kovacs, G.
    Bahlo, J.
    Kluth, S.
    Fink, A. M.
    Cramer, P.
    von Tresckow, J.
    Maurer, C.
    Langerbeins, P.
    Gross-Opphoff-Mueller, C.
    Fischer, K.
    Wendtner, C. -M.
    Kreuzer, K. -A.
    Stilgenbauer, S.
    Hallek, M.
    Eichhorst, B.
    Goede, V.
    Oncology Research and Treatment, 2015, 38 : 91 - 91
  • [47] Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia (vol 25, pg 274, 2011)
    Felipe Casado, Luis
    Garcia Marco, Jose Antonio
    Gilsanz, Florinda
    Gonzalez, Marcos
    Rios, Eduardo
    de la Serna, Javier
    Urbano, Alvaro
    Vicente, Vicente
    Rubio-Terres, Carlos
    Castro, Antonio J.
    GACETA SANITARIA, 2011, 25 (05) : 444 - 444
  • [48] Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry
    Kutsch, Nadine
    Giza, Adam
    Robrecht, Sandra
    Stumpf, Janina
    Federhen, Anno
    Stoltefuss, Andrea
    Vehling-Kaiser, Ursula
    Koenigsmann, Michael
    Tausch, Eugen
    Schneider, Christof
    Stilgenbauer, Stephan
    Illmer, Thomas
    Schlag, Rudolf
    Doerfel, Steffen
    Gaska, Tobias
    Kiehl, Michael
    Mueller-Hagen, Sigrun
    Moorahrend, Enno
    Linde, Hartmut
    Schlenska-Lange, Anke
    von Tresckow, Julia
    Fischer, Kirsten
    Eichhorst, Barbara
    Hallek, Michael
    Fink, Anna Maria
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (02) : 235 - 241
  • [49] Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL).
    Manero, GG
    O'Brien, S
    Cortes, J
    Faderl, S
    Giles, F
    Albitar, M
    Lerner, S
    Kantarjian, H
    Keating, M
    BLOOD, 2001, 98 (11) : 633A - 633A
  • [50] Combined fludarabine, cyclophosphamide, and alemtuzumab (FCC), an active regimen for treated patients with chronic lymphocytic leukemia (CLL)
    Montillo, Marco
    Miqueleiz, Sara
    Tedeschi, Alessandra
    Ricci, Francesca
    Vismara, Eleonora
    Ciapanna, Denis
    Petrizzi, Valeria Belsito
    Crugnola, Monica
    Spriano, Mauro
    Uziel, Lilj
    De Blasio, Angelo
    Spedini, Pierangelo
    Morra, Enrica
    BLOOD, 2007, 110 (11) : 922A - 922A
12345